efavirenz and ER-Negative PR-Negative HER2-Negative Breast Cancer

efavirenz has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Board, PG; Casarotto, MG; Chiou, PT; Dahlstrom, JE; Ohms, S; Rangasamy, D	1

Other Studies

1 other study(ies) available for efavirenz and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Efavirenz as a potential drug for the treatment of triple-negative breast cancers. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:2 Topics: Alkynes; Antineoplastic Agents; Benzoxazines; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cyclopropanes; Down-Regulation; Fatty Acids; Female; Humans; Long Interspersed Nucleotide Elements; Phenotype; Reverse Transcriptase Inhibitors; Transcriptome; Triple Negative Breast Neoplasms	2021

Article

Year

Efavirenz as a potential drug for the treatment of triple-negative breast cancers.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:2

Topics: Alkynes; Antineoplastic Agents; Benzoxazines; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cyclopropanes; Down-Regulation; Fatty Acids; Female; Humans; Long Interspersed Nucleotide Elements; Phenotype; Reverse Transcriptase Inhibitors; Transcriptome; Triple Negative Breast Neoplasms

2021